High Sensitive C - Reactive Protein Levels in Pre and Post Menopausal Healthy Women in Kirkuk City-Iraq

Abstract

A high-sensitivity c-reactive protein (hs-CRP) is one of the acute phase proteins which remarkably increased in systemic inflammation and considered to be an independent risk factor for Cardio Vascular Diseases (CVD). The present study was conducted to evaluate the level of (hs-CRP) in pre and post menopausal women. Two study groups were enrolled in the present study. The first group included (100) samples from healthy pre menopausal women of age ranged (27-45) years. The second group included (90) samples taken from healthy menopausal women their age ranged (51-67) years. The following Kit from (i-CHRomTM hs CRP-25) was used as an immunoassay pattern to evaluate hs-CRP from Boditech Medline. The results of the present study showed a significant differences between the two groups under study, in which the level of hsCRP in pre-was (1.81±1.02) with a significant increase (p<0.05) in post menopausal women (4.02±1.67 mg/L). This study concludes that there is approximately 3 fold significant increase in hs-CRP levels in post menopausal Iraqi women.

Introduction

CRP is a pathogenic inflammatory protein as it was elevated in people with a variety of illnesses including cancer [1]. Is the prototype a cute - phase protein primary synthesized in the liver and its release is stimulated by interleukin 6 (IL-6) [2]. The normal range has to be less than 3mg/L in healthy people in different study have show that the average value between (0.9 -2.05 mg/L).

This protein needs 6-12 hour at the initiation of the disease to reach it peak in blood and could increase to reach 100 folds this protein the half life is 15-25 hour but decrease to its normal values at the recovery state. It has been found that CRP concentration are actually relatively constant in an individual, both with regard to time of day, and over days and months, even over months to years [3].

Two functional properties of CRP have been demonstrated Firstly, it’s ability to recognize foreign pathogens, as well as, phospholipids constituents of damaged cells resulting in elimination of the target cells by the interaction with both humeral and cellular effector systems, secondly, it’s ability to modulate the function of phagocytes cells [4].

A growing body of evidence has supported the idea that cardiovascular diseases including coronary heart disease, ischemic stroke, and acute myocardial infarction, develop, at least in part, because of a chronic low-level CRP of the vascular endothelium [5]. Apparently, besides of being directly involving in low grade chronic systemic inflammation, high-sensitivity CRP (hsCRP) is emerging as the strongest and most independent predictive risk factor for atherosclerosis and CVD [6,7]. Cardiovascular risk assessment cut-offs have been recommended by American Heart Association (AHA) as Low risk: (<1.0 mg/L), Average risk: (1.0 ~ 3.0 mg/L) and High risk: (>3.0 mg/L). The present study was conducted to evaluate the level of (hs-CRP) in pre and post menopausal women in Iraqis’ women.

Materials and Methods

The collection of blood samples was done from January to 30 June 2015. Following the taken of blood sample the serum was submitted to evaluate the hs-crp by using i-CHROMATM hsCRP along with i-CHROMATM Reader is a fluorescence immunoassay that measures CRP in serum, plasma, and whole blood. The test is used as an aid to see infection and inflammation. Immunoassay for Quantitative Measurement of High-Sensitivity C-Reactive Protein (hsCRP) in Human Whole blood with i-CHROMATM Reader System.

Test principle

i-CHROMATM hsCRP is based on fluorescence immunoassay technology 7,8. The i-CHROMATM hsCRP uses a sandwich immunodetection method, such that by mixing detector buffer with blood specimen in test vial, the fluorescence-labelled detector anti-crp antibody in buffer binds to CRP antigen in blood specimen. As the sample mixture is loaded onto the sample well of the test device and migrates the nitrocellulose matrix of test strip by capillary action, the complexes of detector antibody and CRP are captured to anti-crp sandwich pair antibody that has been immobilized on test strip. Thus the more CRP antigen is in blood specimen, the more complexes are accumulated on test strip. Signal intensity of fluorescence of detector antibody reflects amount of CRP captured and is micro processed from i-CHROMATM Reader to show CRP concentration in blood specimen. The default result unit of i-CHROMATM hsCRP is displayed as an mg/L from i-CHROMATM Reader.

Received: December 12, 2015 | Published: February 15, 2016

Fatma Mustafa Mohammed*, Najdat Ali Shafiq and Ektesha Abdulhameed

1College of Dentistry, Tikrit University, Iraq
2Technical College, Kirkuk University, Iraq
3College of Education for Women, Tikrit University, Iraq

*Corresponding author: Fatma Mustafa Mohammed, College of Dentistry, Tikrit University, Tikrit, Iraq, Email: fatmanmufd97@yahoo.com
Procedure

The full procedure was performed following the detailed leaflet of the Kit

A. Image of the test kit (Figure 1)

a. Set a Test Device on a dust-free clean place.
b. Check/insert ID Chip onto the instrument. Make sure that the Test Device lot # matches with ID Chip #.
c. Take out a tube containing Detector Buffer from refrigerator and leave it at room temperature.
d. Make a puncture on the top of the detector tube by inserting an empty blood collection capillary
e. Make a prick on a finger with a lancet. Draw whole blood with a blood collection capillary (Serum or plasma or CRP control can be drawn with the same blood collection capillary) 6. If necessary, wipe out the excess blood outside of the capillary with paper towel or Kim wipes
f. Assemble the capillary and the tube into one.
g. Shake the assembled tube 10 times by inversion to take the blood out of capillary.
h. Remove the cap off the top of tube. Discard two drops of reagent onto the paper towel before applying to the cartridge.
i. Insert Test Device onto the holder of i-CHROMATM Reader. Make sure direction of Test Device and push the device back all the way. Push the “Select” button, and then the holder goes inside the reader. Instrument will automatically read the Test Device after 3 min.
j. Test results will be shown on the display screen of i-CHROMATM Reader.

B. Reading results

i-CHROMATM Reader calculates hsCRP Test results automatically and displays CRP concentration on the screen as form of mg/L. For further information, refer to the Operation Manual for i-CHROMATM Reader.

Statistical Analysis

Statistically data using statistical analysis software (MINITAB) according to T_test test. Have been obtained on the arithmetic mean and standard deviation of the data in the study and use.

R value statistical significance as the level significantly (p <0.05) and significantly high (P <0.01)

Table 1: The effect of age groups on high sensitivity CRP level in healthy pre and post menopausal women.

| Subjects                | Total No. | Study Groups | Mean SD hs-CRP mg/L | Total  |
|-------------------------|-----------|--------------|---------------------|--------|
| Premenopausal Women     | 100       | (27-34) yrs. N= 63 | 1.64 ± 1.01         | 1.81 ± 1.02 |
|                         |           | (35-45) yrs. N= 37 | 1.93 ± 1.09         |        |
| Postmenopausal women    | 90        | (51-58) yrs. N= 67 | 3.69 ± 0.87         | 4.02 ± 1.67 |
|                         |           | (59-67) yrs. N= 23 | 4.33 ± 1.53         |        |

hs-CRP highly sensitive C-reactive Protein.

**Highly significant p≤ 0.01.

*Significant p≤ 0.05.

ns: Non significant p> 0.05.
The result of the present study is agreed with published result of [8] which is been found a significant differences in the levels of the studied hs-crp regarding pre and postmenopausal women with approximately 3 fold increase of hs-crp in the serum of postmenopausal healthy women when compared to pre menopausal.

On the other hand, this study was comparable to that of [9] which found no significant differences between pre and post.

An elevated level of hs-crp in post is contributable to the deposition of lipids according to the lifestyle and estrogen shortage and the role of lipids in the production of proinflammatory mediators like hs-crp. Moreover, the decreased function of ovaries and the significant changes in sex hormone. CRP binds to oxidized LDL which leads to an increase in adhesion molecules promoting complement proteins and trigger inflammation in atherosclerotic plaques. Furthermore, CRP promote the induction of tissue factor, the remarkable factors on monocyte surface which is considered to be one of the important coagulation factors, also increase adhesion molecules and manipulate the production of nitric oxide [8]. The removal of the regulatory effect of estrogens up on hs-crp leads to an increase of hs-crp level in postmenopausal women accumulating the increased risk of cardiovascular disease (CVD).

The cross sectional nature of the present study limits the ability our results to evaluate the relationship between hs-crp and menopause. That needs a long term study with large scale population and sample size. It needs to be emphasized that the significant increased levels of hs-crp in pre and post indicate clearly and increased risk of CVD in postmenopausal women in Kirkuk city in Iraqs women, this increase may be more than the other ethnicities in different world populations. This was clearly indicated by Rifai et al. & michelle et al. [10,11] and the late suggestion of AHA American heart association for those women to be less-clearly sick women and they are candidate to be prevented for CVD. Goff et al. [12] is proved that CRP is a prominent indicator and one of the independent and important risk factors to develop CVD r=r=4.4 in patient’s future, LDL come secondly to hs-crp in this regard [13,14] (Figure 2).

References
1. Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical peptide. Journal of Clinical Biochemistry and Nutrition 41: 50-57.
2. Hackam DG, Anand SS (2003) Emerging risk factor atherosclerotic disease: A critical review of the evidence. JAMA 290(7): 932-940.
3. Li JJ, Fang CH (2004) C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular disease. Med Hypotheses 62(4): 499-506.
4. Park JS, Kim SB (2003) C-reactive protein as a cardiovascular riskfactor and its therapeutic: implications in end-stage renal diseasepatients. Nephrology 8: 540-544.
5. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG (1999) Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 99(7): 855-860.
6. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342(12): 836-843.
7. Taubes G (2002) Does inflammation cut to the heart of the matter? Science 296(5566): 242-245.
8. Suguna S, Mary Pj (2013) Association of menopause with inflammation sensitive protein the c-reactive protein among the indian women. Jemds 52(2): 1044-1053.
9. Sites CK, Toth MJ, Cushman M, L’Hommedieu GD, Thernof A, et al. (2002) Menopause- related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertil Steril 77(1): 128-135.
10. Michelle AA, Ridker Paul M ( 2006) C-Reactive Protein as a Risk Predictor Do Race/Ethnicity and Gender Make a Difference? Circulation14: e67-e74.
11. Albert MA, Ridker PM (2006) C-Reactive Protein as a Risk Predictor Do Race/Ethnicity and Gender Make a Difference? Circulation 114(5): e67-e74.
12. Goff DC, Donald M, Glen B (2014) A report of the American College of cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (63): 25-PA.
13. Rifai N, Ridker PM (2003) Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. ClinChem 49(4): 666-669.
14. Paradyhan A, Manson J, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of development type 2 diabetes mellitus. JAMA 286(3): 327-334.